Literature DB >> 20186503

Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.

Elias Sozopoulos1, Helen Litsiou, Gerassimos Voutsinas, Nikolaos Mitsiades, Nikolaos Anagnostakis, Thomais Tseva, Efstratios Patsouris, Sofia Tseleni-Balafouta.   

Abstract

PI3K/Akt signaling pathway plays critical role in many cell processes. There is indication that enhanced activation of PI3K/Akt cascade is implicated in thyroid tumors. Aim of this study was to evaluate the mutational status and expression of PI3K/Akt pathway mediators in papillary thyroid carcinoma in Greece. We evaluated the presence of mutations in PIK3CA (exons 9 and 20), AKT1 (exons 6-11), AKT2 (exons 6-11), AKT3 (exons 5-10), PTEN (exons 3-8), and PDPK1 (exons 4-10) genes in 83 papillary thyroid carcinomas by DNA sequencing. The expression levels of phospho-Akt and insulin-like growth factor I receptor (IGF-IR) were evaluated by immunohistochemistry. PIK3CA mutations were found in three samples. The analysis of AKT1 revealed one silent mutation in exon 9 (G726A) in 16 samples. One specimen carried an AKT3 mutation. One missense mutation was found in one sample in PTEN. No mutations were found in AKT2 and PDPK1. Increased levels of phosphorylated total Akt and IGF-IR were identified in some papillary cancers. Our findings indicate that PI3K/Akt signaling pathway is activated in some papillary tumors. However, mutations in genes coding most mediators of the pathway have not been proven to be the major modus of enhanced activation. These data suggest a potential role for PI3K/Akt-mediated signaling in papillary thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186503     DOI: 10.1007/s12022-010-9112-0

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  66 in total

1.  Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects.

Authors:  G De Vita; M T Berlingieri; R Visconti; M D Castellone; G Viglietto; G Baldassarre; M Zannini; A Bellacosa; P N Tsichlis; A Fusco; M Santoro
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

Review 2.  The IGF-1 receptor in cancer biology.

Authors:  Renato Baserga; Francesca Peruzzi; Krysztof Reiss
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

3.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells.

Authors:  M Ivan; J A Bond; M Prat; P M Comoglio; D Wynford-Thomas
Journal:  Oncogene       Date:  1997-05-22       Impact factor: 9.867

Review 4.  Oncogenic PI3K and its role in cancer.

Authors:  Yardena Samuels; Kajsa Ericson
Journal:  Curr Opin Oncol       Date:  2006-01       Impact factor: 3.645

5.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

Authors:  P L Dahia; D J Marsh; Z Zheng; J Zedenius; P Komminoth; T Frisk; G Wallin; R Parsons; M Longy; C Larsson; C Eng
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

6.  Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1.

Authors:  M J Wick; L Q Dong; R A Riojas; F J Ramos; F Liu
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

7.  Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours.

Authors:  P Kornprat; P Rehak; J Rüschoff; C Langner
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

8.  Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.

Authors:  Peng Hou; Dingxie Liu; Yuan Shan; Shuiying Hu; Kimberley Studeman; Stephen Condouris; Yangang Wang; Ariel Trink; Adel K El-Naggar; Giovanni Tallini; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

9.  Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer.

Authors:  Geetika Chakravarty; Alfredo A Santillan; Chad Galer; Henry P Adams; Abdal K El-Naggar; Samar A Jasser; Sayed Mohsin; Debasis Mondal; Gary L Clayman; Jeffrey N Myers
Journal:  Exp Biol Med (Maywood)       Date:  2009-01-28

10.  RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.

Authors:  Kiyohiro Hamatani; Hidetaka Eguchi; Reiko Ito; Mayumi Mukai; Keiko Takahashi; Masataka Taga; Kazue Imai; John Cologne; Midori Soda; Koji Arihiro; Megumu Fujihara; Kuniko Abe; Tomayoshi Hayashi; Masahiro Nakashima; Ichiro Sekine; Wataru Yasui; Yuzo Hayashi; Kei Nakachi
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

View more
  11 in total

1.  Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.

Authors:  Naoki Oishi; Tetsuo Kondo; Aya Ebina; Yukiko Sato; Junko Akaishi; Rumi Hino; Noriko Yamamoto; Kunio Mochizuki; Tadao Nakazawa; Hiroshi Yokomichi; Koichi Ito; Yuichi Ishikawa; Ryohei Katoh
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

2.  Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.

Authors:  Avaniyapuram Kannan Murugan; Jianli Dong; Jingwu Xie; Mingzhao Xing
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

3.  Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Authors:  Minjing Zou; Essa Y Baitei; Ali S Alzahrani; Faisal S BinHumaid; Dania Alkhafaji; Roua A Al-Rijjal; Brian F Meyer; Yufei Shi
Journal:  Thyroid       Date:  2014-06-10       Impact factor: 6.568

Review 4.  PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.

Authors:  Zahra Nozhat; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

5.  Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.

Authors:  Mark A Applebaum; Dafydd G Thomas; Todd Hembrough; Jon Burrows; Andrew E Horvai; Elizabeth R Lawlor; Steven G DuBois
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-09

Review 6.  IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.

Authors:  Apostolos Karagiannis; Eva Kassi; Antonios Chatzigeorgiou; Michael Koutsilieris
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

7.  Expression, localization, and phosphorylation of Akt1 in benign and malignant thyroid lesions.

Authors:  Anna Krześlak; Lech Pomorski; Anna Lipińska
Journal:  Endocr Pathol       Date:  2011-12       Impact factor: 3.943

8.  PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma.

Authors:  S Beg; A K Siraj; Z Jehan; S Prabakaran; S S Al-Sobhi; M Al-Dawish; F Al-Dayel; K S Al-Kuraya
Journal:  Br J Cancer       Date:  2015-05-19       Impact factor: 7.640

9.  Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.

Authors:  Berna B Duman; Oğuz I Kara; Aysum Uğuz; Berna T Ates
Journal:  Contemp Oncol (Pozn)       Date:  2014-07-04

10.  Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population.

Authors:  Hye Sook Min; Chul Lee; Kyeong Cheon Jung
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.